What is the recommended dosage, technique, and follow‑up for intralesional Kenalog (triamcinolone acetonide) injection of a deep acne nodule in an otherwise healthy adolescent or adult without infection or contraindications?

Intralesional Kenalog for Deep Acne Nodules

For deep acne nodules, inject intralesional triamcinolone acetonide at a concentration of 2.5 mg/mL (or lower at 0.63-1.0 mg/mL to minimize atrophy risk), using a volume of 0.05 mL or less per lesion, injected into the center of the nodule as an adjuvant therapy for rapid inflammation reduction and scar prevention. 1

Guideline-Based Recommendation

The 2024 American Academy of Dermatology guidelines explicitly recommend intralesional corticosteroid injections as a good practice statement for larger acne papules or nodules as adjuvant therapy 1. The guidelines emphasize:

• Use judiciously for patients at risk of acne scarring and/or when rapid improvement in inflammation and pain is needed
• Lower concentration and volume minimize risks of local adverse events (atrophy, hypopigmentation) 1

This is positioned as an adjunct to standard topical and systemic therapies, not monotherapy.

Specific Dosing Protocol

Concentration

2.5 mg/mL is the most commonly used concentration among dermatologists (52.5% in practice surveys) 2. However, evidence supports that:

• 0.63 mg/mL is equally efficacious to 2.5 mg/mL for nodulocystic acne 3
• Recent data shows 0.1-0.2% (1-2 mg/mL) concentrations are effective, with 0.2% showing better results for more severe lesions 4
• Lower concentrations reduce atrophy risk while maintaining efficacy 1, 3

Practical recommendation: Start with 1.0-2.5 mg/mL; use lower concentrations (0.63-1.0 mg/mL) for facial lesions or patients with darker skin tones where atrophy/hypopigmentation is more visible.

Volume

0.05 mL per lesion is the most frequently used volume (42.3% of practitioners) 2. The FDA label indicates:

• Initial doses for smaller areas: 2.5-5 mg total
• For intra-articular use (as reference): up to 10 mg for smaller areas 5

Practical recommendation: Inject 0.03-0.05 mL per nodule, adjusting based on lesion size. Avoid exceeding 0.1 mL per lesion to minimize atrophy risk.

Injection Technique

Depth and Location

• 61.6% of dermatologists inject into the center of the lesion 2
• Inject intradermally into the nodule itself, not subcutaneously around it
• The goal is to deliver medication directly into the inflammatory mass
• Avoid injecting into surrounding normal tissue, which increases atrophy risk 5

Procedure Steps

1. Cleanse the area with alcohol
2. Use a 30-gauge needle (standard for intralesional injections)
3. Insert needle into the center of the nodule at a shallow angle
4. Inject slowly until slight blanching or resistance is felt
5. Withdraw needle and apply gentle pressure

Critical Pitfall

Subcutaneous injection causes fat atrophy 5. The FDA label for intramuscular Kenalog explicitly warns that "atrophy of subcutaneous fat may occur if the injection is not properly given" 5. This is the most common adverse effect when technique is suboptimal.

Expected Outcomes and Follow-Up

Efficacy Timeline

• Improvement within 48 hours to 1 week in most cases 6
• Complete resolution: median 4.6-8.1 days depending on concentration 7
• 70-100% improvement rate at one week 6
• Single injection is often sufficient, though repeat injections may be needed 5

Follow-Up Schedule

• Reassess at 1 week to evaluate response
• If inadequate response, consider:
  • Repeat injection (can be done weekly if needed)
  • Higher concentration (if started low)
  • Alternative systemic therapy if multiple nodules persist

Adverse Events

Atrophy and hypopigmentation are the main concerns:

• Occur in <1% of patients when proper technique is used 2
• When atrophy occurs, it typically lasts >6 months (48.4% of cases) 2
• No severe adverse events reported in recent studies 4, 7
• Risk minimized by: lower concentrations, smaller volumes, proper injection depth 1

Patient Counseling

50.5% of dermatologists counsel on hypopigmentation/atrophy risks before every injection 2. Key points to discuss:

• Expect rapid improvement (days, not weeks)
• Small risk of temporary skin depression or lightening at injection site
• This is adjunctive therapy—continue prescribed topical/oral medications
• Single treatment often sufficient, but repeat may be needed
• No need for routine monitoring in healthy patients 5

Contraindications and Precautions

From FDA labeling 5:

• Do not use if infection is present in or around the lesion
• Avoid in patients with known hypersensitivity to corticosteroids
• Use caution in patients with history of keloid formation
• Not for intravenous use (this is a suspension) 5
• Benzyl alcohol preservative: use caution in neonates (not typically relevant for acne patients) 5

Integration with Standard Acne Therapy

This is adjunctive therapy—patients should simultaneously receive 1:

• Topical retinoids (adapalene, tretinoin, or tazarotene)
• Benzoyl peroxide (to prevent antibiotic resistance)
• Oral antibiotics (doxycycline preferred) if moderate-to-severe inflammatory acne
• Consider oral isotretinoin if severe, scarring, or treatment-resistant 1

The intralesional injection addresses the acute nodule while systemic therapy prevents new lesions.